medigraphic.com
Academia Mexicana de Neurología, A.C.

2019, Number 1

<< Back Next >>

Rev Mex Neuroci 2019; 20 (1)

Infusion therapies in advanced Parkinson’s disease|

Navarro-Roa C, Rodríguez-Violante M, Cervantes-Arriaga A

Language: Spanish
References: 59
Page: 3-13
PDF size: 174.64 Kb.


ABSTRACT

Parkinson’s disease (PD) is a neurodegenerative disorder whose treatment is symptomatic, usually initiated as monotherapy, but with the progression of symptoms and the appearance of motor complications the use of polytherapy is frequent. The patient with advanced disease with an inadequate response to treatment with oral or transdermal drugs may be a candidate for device-assisted therapies such as deep brain stimulation, continuous subcutaneous apomorphine infusion (CSAI) and levodopa/carbidopa intestinal gel (LCIG). The last two treatments also receive the denomination of infusion therapies. The present review has the objective of presenting the historical background, pharmacological characteristics, indications, contraindications, initiation and dosage, effectivity on motor and non-motor symptoms, safety profile and selection of the ideal candidate for CSAI and LCIG therapies for patients with advanced PD.


REFERENCES

  1. Blin P, Dureau-Pournin C, Foubert-Samier A, Grolleau A, Corbillon E, Jové J, et al. Parkinson’s disease incidence and prevalence assessment in France using the national healthcare insurance database. Eur J Neurol. 2015;22(3):464-71.

  2. Enders D, Balzer-Geldsetzer M, Riedel O, Dodel R, Wittchen HU, Sensken SC, et al. Prevalence, duration and severity of Parkinson’s disease in Germany: A combined meta-analysis from literature data and outpatient samples. Eur Neurol. 2017;78(3-4):128-36.

  3. Morgan JC, Fox SH. Treating the motor symptoms of Parkinson disease. Continuum (Minneap Minn). 2016;22(4 Movement Disorders):1064-85.

  4. Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES. Consensus on the definition of advanced Parkinson’s disease: A neurologists-based Delphi Study (CEPA Study). Parkinsons Dis. 2017;2017:4047392.

  5. Tomiyama M. Symptoms and pathophysiology of dyskinesias. Brain Nerve. 2017;69:1409-16.

  6. Timpka J, Nitu B, Datieva V, Odin P, Antonini A. Device-aided treatment strategies in advanced Parkinson’s disease. Int Rev Neurobiol. 2017;132:453-74.

  7. Djamshidian A, Poewe W. Apomorphine and levodopa in Parkinson’s disease: Two revolutionary drugs from the 1950’s. Parkinsonism Relat Disord. 2016;33:S9-12.

  8. Taba P, Lees A, Stern G. Erich Harnack (1852-1915) and a short history of apomorphine. Eur Neurol. 2013;69(6):321-4.

  9. Przedborski S1, Levivier M, Raftopoulos C, Naini AB, Hildebrand J. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov Disord. 1995;10(1):28-36.

  10. Ostergaard L, Werdelin L, Odin P, Lindvall O, Dupont E, Christensen PB, et al. Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995;58(6):681-7.

  11. Trenkwalder C, Chaudhuri KR, García Ruiz PJ, LeWitt P, Katzenschlager R, Sixel-Döring F, et al.; Expert Consensus Group for Use of Apomorphine in Parkinson’s Disease, Baker M, Ceballos-Baumann A, Deuschl G, Drapier S, Ebersbach G, Evans A, et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease--Clinical practice recommendations. Parkinsonism Relat Disord. 2015; 21(9):1023-30.

  12. Bhidayasiri R, Chaudhuri KR, LeWitt P, Martin A, Boonpang K, van Laar T. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses. Clin Neuropharmacol. 2015;38(3):89-103.

  13. Fernández-Pajarín G, Sesar Á, Ares B, Castro A. Evaluating the efficacy of nocturnal continuous subcutaneous apomorphine infusion in sleep disorders in advanced Parkinson’s disease: The APO-NIGHT Study. J Parkinsons Dis. 2016;6(4):787-92.

  14. Arnold G, Schwarz J, Macher C, Oertel WH. Domperidone is superior to ondansetron in acute apomorphine challenge in previously untreated parkinsonian patients - A double blind study. Parkinsonism Relat Disord. 1997;3(4):191-3.

  15. Lertxundi U, Domingo-Echaburu S, Soraluce A, García M, Ruiz-Osante B, Aguirre C. Domperidone in Parkinson’s disease: a perilous arrhythmogenic or the gold standard? Curr Drug Saf. 2013;8(1):63-8.

  16. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649-53.

  17. Moreno López CL, Bernal Pacheco O, Barrios Vincos G, Arango Uribe G, Cerquera Cleves C, Orozco Vélez JL, et al. Consenso de la Asociación Colombiana de Neurología sobre el uso de apomorfina en la enfermedad de Parkinson. Acta Neurol Colomb. 2018;34(1):25-39.

  18. Grandas F. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease. Expert Rev Neurother. 2013;13(12):1343-53.

  19. Borgemeester RW, Lees AJ, van Laar T. Parkinson’s disease, visual hallucinations and apomorphine: A review of the available evidence. Parkinsonism Relat Disord. 2016;27:35-40.

  20. Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174(12):1930-3.

  21. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry. 1998;65(5):709-16.

  22. Bhidayasiri R, Garcia Ruiz PJ, Henriksen T. Practical management of adverse events related to apomorphine therapy. Parkinsonism Relat Disord. 2016;33(Suppl 1):S42-8.

  23. Bacchi S, Chim I, Kramer P, Postuma RB. Domperidone for hypotension in Parkinson’s disease: A systematic review. J Parkinsons Dis. 2017; 7(4):603-17.

  24. Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on–off oscillations. Lancet. 1988;1(8582):403-6.

  25. Chaudhuri KR, Critchley P, Abbott RJ, Pye IF, Millac PA. Subcutaneous apomorphine for on–off oscillations in Parkinson’s disease. Lancet. 1988;2(8622):1260.

  26. Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17(9):749-59.

  27. García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro García A, Alonso Frech F, Alvarez López M, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord. 2008;23(8):1130‑6.

  28. Sesar Á, Fernández-Pajarín G, Ares B, Rivas MT, Castro A. Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients. J Neurol- 2017;264(5):946-54.

  29. Rosa-Grilo M, Qamar MA, Evans A, Chaudhuri KR. The efficacy of apomorphine - A non-motor perspective. Parkinsonism Relat Disord. 2016;33 Suppl 1:S28-35.

  30. Todorova A, Ray Chaudhuri K. Subcutaneous apomorphine and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2013; 19(12):1073-8.

  31. Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F, et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson’s disease: a follow-up of two years. Arch Gerontol Geriatr Suppl. 2004;(9):291-6.

  32. Bestetti A, Capozza A, Lacerenza M, Manfredi L, Mancini F. Delayed gastric emptying in advanced Parkinson disease: Correlation with therapeutic doses. Clin Nucl Med. 2017;42(2):83-7.

  33. Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol. 1986;20(2):262-5.

  34. Kurlan R, Nutt JG, Woodward WR, Rothfield K, Lichter D, Miller C, et al. Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol. 1988;23(6):589-95.

  35. Othman AA, Dutta S. Population pharmacokinetics of levodopa in subjects with advanced Parkinson’s disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. Br J Clin Pharmacol. 2014;78(1):94-105.

  36. Palhagen SE, Sydow O, Johansson A, Nyholm D, Holmberg B, Widner H, et al. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson’s disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism Relat Disord. 2016;29:17-23.

  37. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson’s disease. Eur J Neurol. 2012; 19:1079-85.

  38. Zibetti M, Merola A, Ricchi V, Marchisio A, Artusi CA, Rizzi L, et al. Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study. J Neurol. 2013;260:105-14.

  39. Devos D; French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord. 2009; 24(7):993-1000.

  40. Albanese A, Bonuccelli U, Brefel C, Chaudhuri KR, Colosimo C, Eichhorn T, et al. Consensus statement on the role of acute dopaminergic challenge in Parkinson’s disease. Mov Disord. 2001;16(2):197-201.

  41. Lew MF, Slevin JT, Krüger R, Martínez Castrillo JC, Chatamra K, Dubow JS, et al. Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. Parkinsonism Relat Disord. 2015; 21(7):742-8.

  42. Santos-Garcia D, de Deus-Fonticoba T. Initiation of levodopa enteral infusion: is always the test with nasojejunal tube really necessary? Rev Neurol. 2018;67(5):192-3.

  43. Santos García D, Martínez Castrillo JC, Puente Périz V, Seoane Urgorri A, Fernández Díez S, Benita León V, et al. Clinical management of patients with advanced Parkinson’s disease treated with continuous intestinal infusion of levodopa/carbidopa. Neurodegener Dis Manag. 2016; 6(3):187-202.

  44. Cheron J, Deviere J, Supiot F, Ballarin A, Eisendrath P, Toussaint E, et al. The use of enteral access for continuous delivery of levodopa-carbidopa in patients with advanced Parkinson’s disease. United European Gastroenterol J. 2017;5(1):60-8.

  45. Pedersen SW, Clausen J, Gregerslund MM. Practical guidance on how to handle levodopa/carbidopa intestinal gel therapy of advanced PD in a movement disorder clinic. Open Neurol J. 2012;6:37-50.

  46. Fasano A, Liu LW, Poon YY, Lang AE. Initiating intrajejunal infusion of levodopa/carbidopa intestinal gel: an outpatient model. Mov Disord. 2015; 30(4):598-99.

  47. Catalán MJ, Antonini A, Calopa M, Bajenaru O, de Fábregues O, Mínguez-Castellanos A, et al. Can suitable candidates for levodopa/ carbidopa intestinal gel therapy be identified using current evidence? eNeurologicalSci. 2017;8:44-53.

  48. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al.; LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double- dummy study. Lancet Neurol. 2014;13(2):141-9.

  49. Sensi M, Cossu G, Mancini F, Pilleri M, Zibetti M, Modugno N, et al.; Italian levodopa carbidopa intestinal gel working group. Which patients discontinue? Issues on levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism Relat Disord. 2017;38:90-2.

  50. Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64(2):216‑23.

  51. Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord. 2015;30(4):500‑9.

  52. Wang L, Li J, Chen J. Levodopa-carbidopa intestinal gel in Parkinson’s disease: A systematic review and meta-analysis. Front Neurol. 2018; 30:9:620.

  53. Antonini A, Yegin A, Preda C, Bergmann L, Poewe W; GLORIA study investigators and coordinators. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015;21(3):231-5.

  54. Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;20:1-11.

  55. Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez- Martin P, et al.; National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: Consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21(10):1133-44.

  56. Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30(4):510-6.

  57. Vivancos-Matellano F, Garcia-Ruiz AJ, Garcia-Agua SN. Pharmacoeconomic study of the treatment of advanced Parkinson’s disease. Rev Neurol. 2016;63(12):529-36.

  58. Walter E, Odin P. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany. J Med Econ. 2015;18(2):155-65.

  59. Lowin J, Sail K, Baj R, Jalundhwala Y, Marshall TS, Konwea H, et al. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease. J Med Econ. 2017;20(11):1207-15.




2020     |     www.medigraphic.com